Drug Profile
GI 448
Latest Information Update: 30 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Japan
- Class Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycobacterium avium complex infections
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Mycobacterium avium complex infections in Japan (unspecified route)
- 28 Feb 2003 Dainabot has merged with Hokuriku Seiyaku to form Abbott Japan
- 03 Jan 2002 New profile